Executive vice president, North America Operations, and president, Novo Nordisk, Novo Nordisk
Since joining the pharmaceutical company in 2017, Langa has worked to further its mission to expand options for those living with chronic conditions, including cardiometabolic disease. Under Langa’s leadership, Novo Nordisk’s drugs have received U.S. Food and Drug Administration approval to treat Type 2 diabetes and manage weight. He also brought to market a once-weekly growth hormone treatment for children and adults. Langa is helping to steer Novo Nordisk’s ongoing journey to becoming an innovation incubator, with goals of addressing sickle cell disease, cardiovascular disease, Alzheimer’s disease, chronic kidney disease and other complex conditions.